Cargando…
Inhibition of B7-1 (CD80) by RhuDex(®) reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions
BACKGROUND: Atherosclerosis is based on a chronic inflammatory process including the innate and adaptive immune response. Costimulatory molecules and their receptors provide decisive signals for antigen-specific cell activation. The contribution of B7-related pathways to atherosclerosis has hardly b...
Autores principales: | Doesch, Andreas O, Zhao, Li, Gleissner, Christian A, Akhavanpoor, Mohammadreza, Rohde, David, Okuyucu, Deniz, Hakimi, Maani, Dengler, Thomas J, Katus, Hugo A, Erbel, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026407/ https://www.ncbi.nlm.nih.gov/pubmed/24872677 http://dx.doi.org/10.2147/DDDT.S59594 |
Ejemplares similares
-
Immunomodulation of human intestinal T cells by the synthetic CD80 antagonist RhuDex®
por: Heninger, Anne-Kristin, et al.
Publicado: (2014) -
CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions
por: Akhavanpoor, Mohammadreza, et al.
Publicado: (2014) -
Adventitial inflammation and its interaction with intimal atherosclerotic lesions
por: Akhavanpoor, Mohammadreza, et al.
Publicado: (2014) -
Inflammatory therapeutic targets in coronary atherosclerosis—from molecular biology to clinical application
por: Linden, Fabian, et al.
Publicado: (2014) -
CXCL4 Plasma Levels Are Not Associated with the Extent of Coronary Artery Disease or with Coronary Plaque Morphology
por: Erbel, Christian, et al.
Publicado: (2015)